User profiles for Pratap Neelakantan
 | pratap neelakantanRoyal Berkshire Hospital NHS Foundation Trust Verified email at nhs.net Cited by 276 |
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6 months
after starting treatment with tyrosine kinase inhibitors strongly predicts clinical outcomes …
after starting treatment with tyrosine kinase inhibitors strongly predicts clinical outcomes …
Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy
…, P Polzella, N Gray, P Neelakantan… - European journal of …, 2020 - Wiley Online Library
Objectives We sought to characterise the outcomes of patients with haematological
malignancy and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in …
malignancy and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in …
Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK …
…, MF McMullin, P Neelakantan… - British journal of …, 2021 - Wiley Online Library
Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes,
prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however…
prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however…
[HTML][HTML] Combined IL‐6 and JAK/STAT inhibition therapy in COVID‐19‐related sHLH, potential game changer
…, TNT Nguyen, E Beacham, P Neelakantan - British journal of …, 2020 - ncbi.nlm.nih.gov
Coronavirus disease 2019 (COVID-19), caused by the novel SARS-CoV-2, leads to
significant mortality and morbidity with increasing evidence for inflammatory pathways being …
significant mortality and morbidity with increasing evidence for inflammatory pathways being …
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor …
P Neelakantan, D Marin, M Laffan, J Goldman… - …, 2012 - haematologica.org
©Ferrata Storti Foundation Page 1 Platelet dysfunction associated with ponatinib, a new pan
BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase …
BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase …
[HTML][HTML] Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
…, CH Teh, F Wadelin, J Dhanapal, P Neelakantan… - Leukemia, 2021 - nature.com
The COVID-19 pandemic caused by the spread of SARS-CoV-2 virus has already had a
catastrophic impact with more than 1.4 million deaths worldwide as of 29 November 2020 [1]. …
catastrophic impact with more than 1.4 million deaths worldwide as of 29 November 2020 [1]. …
The management of myelofibrosis: a British Society for Haematology Guideline
…, J Nangalia, P Neelakantan… - British journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
… 19 , Pratap Neelakantan …
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
…, S Ackroyd, J Ewing, P Neelakantan… - Therapeutic …, 2022 - journals.sagepub.com
Background: Myelofibrosis (MF) is a blood cancer associated with splenomegaly, blood
count abnormalities, reduced life expectancy and high prevalence of disease-associated …
count abnormalities, reduced life expectancy and high prevalence of disease-associated …
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline
…, A McGregor, P Neelakantan… - British journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
… 17 , Pratap Neelakantan …
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side …
P Neelakantan, K Rezvani, P May… - British journal of …, 2014 - search.ebscohost.com
The article focuses on a study which examines the cytogenetic response on Imatinib drug
given to patients with chronic myeloid leukaemia as first line tyrosine kinase inhibitor (TKI) …
given to patients with chronic myeloid leukaemia as first line tyrosine kinase inhibitor (TKI) …